Sirolimus Tablet, Film Coated
Product Images NDC 50268-827

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Sirolimus (NDC 50268-827). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avpak, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (B28dd501 1384 4376 Be15 Ce15c0d22439 01)

Chemical structure of sirolimus shown as a detailed molecular diagram with various rings, bonds, and functional groups depicted.*

FDA Label Image

Figure 1 (B28dd501 1384 4376 Be15 Ce15c0d22439 02)

A line graph comparing forced expiratory volume in 1 second (FEV1) in liters over a 24-month period between Sirolimus and placebo groups. The chart is divided into Treatment and Observation phases, showing higher FEV1 values for the Sirolimus group throughout. Number of subjects for each group is provided below the graph for various months.*

FDA Label Image

1 (827 13)

Label for Sirolimus Tablets 0.5 mg, oral film-coated tablets, available in a package of 30 tablets (3 x 10 unit doses). The label includes the NDC 50268-827-13, manufacturer AvPAK, and storage instructions at 20°C to 25°C. The label states "Rx Only" and cautions to keep out of reach of children.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.